The researchers also demonstrated that in two highly aggressive TNBC cell lines, MDA‐MB‐231 and MDA‐MB‐468, GLP‐1 receptor activation by liraglutide may promote breast cancer cell growth through the NOX4/ROS/VEGF pathway and that liraglutide acted as a tumor promoter at a concentration of 100 nM in vitro [102]. The gene discussed is GLP1R; the disease is neoplasm.